The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 29, 2025
Filed:
May. 27, 2021
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Zhenting Gao, Shanghai, CN;
Haibing Guo, Shanghai, CN;
Ming Li, Shanghai, CN;
Kun Chin Liu, Shanghai, CN;
Chunliang Lu, Shanghai, CN;
Zhuming Sun, Shanghai, CN;
Yihui Zhu, Warren, NJ (US);
Assignee:
CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD., Shanghai, CN;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 473/34 (2006.01); A61K 31/437 (2006.01); A61K 31/52 (2006.01); A61K 31/53 (2006.01); A61P 35/02 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 473/34 (2013.01); A61K 31/437 (2013.01); A61K 31/52 (2013.01); A61K 31/53 (2013.01); A61P 35/02 (2018.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).